Clinical Trial Detail

NCT ID NCT03255083
Title DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Daiichi Sankyo, Inc.
Indications

non-small cell lung carcinoma

lung adenocarcinoma

Therapies

DS-1205c + Osimertinib

Age Groups: adult senior

Additional content available in CKB BOOST